Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Study sponsor: Summit Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-04Estimated
Enrollment · participants780Estimated
Source updated2026-11-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.